Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Influenza

Free Subscription 25.03.2024 5 Ann Intern Med 4 Antiviral Res 1 BMC Pediatr 2 BMJ 2 Epidemiol Infect 2 J Immunol 9 J Infect 3 J Virol 4 JAMA 1 MMWR Morb Mortal Wkly Rep 3 N Engl J Med 1 PLoS Biol 1 PLoS Comput Biol 31 PLoS One 2 Proc Natl Acad Sci U S A 27 Vaccine 1 Virology 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
   Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial.
   Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
   PubMed         Abstract available
   
   
2. KIM MS, Lee H, Lee SW, Kwon R, et al
   Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational Cohort Study.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1831.
   PubMed         Abstract available
   
   
3. GRANWEHR BP
   In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0006.
   PubMed         Abstract available
   
   
4. PAULES CI, Wang J, Tomashek KM, Bonnett T, et al
   A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
   Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593.
   PubMed         Abstract available
   
   
5. OLFSON M, McClellan C, Zuvekas SH, Wall M, et al
   Trends in Psychological Distress and Outpatient Mental Health Care of Adults During the COVID-19 Era.
   Ann Intern Med. 2024 Feb 6. doi: 10.7326/M23-2824.
   PubMed         Abstract available
   
   

   
   Antiviral Res

6. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
   SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
   Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
   PubMed         Abstract available
   
   
7. NOBORI H, Baba K, Kuroda T, Baba K, et al
   Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
   Antiviral Res. 2024;224:105852.
   PubMed         Abstract available
   
   
8. LI H, Sun M, Lei F, Liu J, et al
   Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
   Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
   PubMed         Abstract available
   
   
9. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
   The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
   Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

10. JAMALI Z, Mohammadpour N, Sinaei R, Jafari M, et al
    The footprint of SARS-COV-2 infection in neonatal late sepsis.
    BMC Pediatr. 2024;24:184.
    PubMed         Abstract available
    
    

    
    BMJ

11. MCKEEVER V
    Long covid and myalgic encephalomyelitis/chronic fatigue syndrome are overlapping conditions.
    BMJ. 2024;384:q613.
    PubMed        
    
    
12. WISE J
    RSV: Paediatricians call on government to expedite infant vaccination programme.
    BMJ. 2024;384:q706.
    PubMed        
    
    

    
    Epidemiol Infect

13. PENG L, Huang X, Wang C, Xin H, et al
    Comparative epidemiology of outbreaks caused by SARS-CoV-2 Delta and Omicron variants in China.
    Epidemiol Infect. 2024;152:e43.
    PubMed         Abstract available
    
    
14. YAP WK, Attwell K
    Medical exemptions to mandatory vaccinations: The state of play in Australia and a pressure point to watch.
    Epidemiol Infect. 2024;152:e40.
    PubMed         Abstract available
    
    

    
    J Immunol

15. KUNDURA L, Cezar R, Ballongue E, Andre S, et al
    Low Percentage of Perforin-Expressing NK Cells during Severe SARS-CoV-2 Infection: Consumption Rather than Primary Deficiency.
    J Immunol. 2024;212:1105-1112.
    PubMed         Abstract available
    
    
16. ABE K, Beer JC, Nguyen T, Ariyapala IS, et al
    Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort.
    J Immunol. 2024;212:1244-1253.
    PubMed         Abstract available
    
    

    
    J Infect

17. LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al
    Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic Review and Meta-analysis for Enhanced Disease Surveillance.
    J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024.
    PubMed         Abstract available
    
    
18. HUNG KC, Chen IW, Sun CK
    Pulmonary dysfunction severity may impact optimal dexamethasone dosing in patients with COVID-19.
    J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024.
    PubMed        
    
    
19. XIE L, Luo G, Yang Z, Wu WC, et al
    The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract.
    J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024.
    PubMed         Abstract available
    
    
20. KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al
    Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein SARS-CoV-2 Vaccines.
    J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119.
    PubMed        
    
    
21. YAO Z, Zhang L, Duan Y, Tang X, et al
    Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
    J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121.
    PubMed         Abstract available
    
    
22. HITES M, Massonnaud CR, Jamard S, Goehringer F, et al
    Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial.
    J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120.
    PubMed        
    
    
23. ZHOU J, Lan L, Ai S, Lin J, et al
    People Living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention.
    J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122.
    PubMed        
    
    
24. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    PubMed        
    
    
25. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    PubMed         Abstract available
    
    

    
    J Virol

26. MARTINS M, Nooruzzaman M, Cunningham JL, Ye C, et al
    The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection.
    J Virol. 2024 Feb 29:e0190223. doi: 10.1128/jvi.01902.
    PubMed         Abstract available
    
    
27. VANSLAMBROUCK JM, Neil JA, Rudraraju R, Mah S, et al
    Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.
    J Virol. 2024 Feb 9:e0180223. doi: 10.1128/jvi.01802.
    PubMed         Abstract available
    
    
28. NIU S, Zhao Z, Liu Z, Rong X, et al
    Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
    J Virol. 2024 Feb 2:e0115723. doi: 10.1128/jvi.01157.
    PubMed         Abstract available
    
    

    
    JAMA

29. LU Y, Matuska K, Nadimpalli G, Ma Y, et al
    Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
    JAMA. 2024;331:938-950.
    PubMed         Abstract available
    
    
30. GRAETZ N, Hepburn P, Gershenson C, Porter SR, et al
    Examining Excess Mortality Associated With the COVID-19 Pandemic for Renters Threatened With Eviction.
    JAMA. 2024;331:592-600.
    PubMed         Abstract available
    
    
31. HARRIS E
    Missed Vaccine Doses Tied to Worse COVID-19 Outcomes.
    JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28340.
    PubMed        
    
    
32. RUBIN R
    Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    JAMA. 2024 Jan 31. doi: 10.1001/jama.2023.28254.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

33. YOUSAF AR, Lindsey KN, Wu MJ, Shah AB, et al
    Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children - United States, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:225-228.
    PubMed        
    
    

    
    N Engl J Med

34. HAVIARI S, Massonnaud CR, Dupont A
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155.
    PubMed        
    
    
35. WOO EJ, Hulse AN
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155-1156.
    PubMed        
    
    
36. HSIAO A, Fireman B, Klein NP
    Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply.
    N Engl J Med. 2024;390:1156.
    PubMed        
    
    

    
    PLoS Biol

37. BEKDASH R, Yoshida K, Nair MS, Qiu L, et al
    Developing inhibitory peptides against SARS-CoV-2 envelope protein.
    PLoS Biol. 2024;22:e3002522.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

38. JIJON S, Czuppon P, Blanquart F, Debarre F, et al
    Using early detection data to estimate the date of emergence of an epidemic outbreak.
    PLoS Comput Biol. 2024;20:e1011934.
    PubMed         Abstract available
    
    

    
    PLoS One

39. SUWANBAMRUNG C, Srinam B, Promkool P, Suwannakarn W, et al
    Uptake of COVID-19 vaccine among high-risk urban populations in Southern Thailand using the COM-B model.
    PLoS One. 2024;19:e0300509.
    PubMed         Abstract available
    
    
40. TEFERA Y, Kumie A, Hailemariam D, Wakuma S, et al
    Impact of Covid -19 incidence rate and government-initiated risk communication measures on individual's NPI practices.
    PLoS One. 2024;19:e0283294.
    PubMed         Abstract available
    
    
41. LI Y, Li J, He J, Tao C, et al
    AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events.
    PLoS One. 2024;19:e0300919.
    PubMed         Abstract available
    
    
42. DEWA LH, Roberts L, Choong E, Crandell C, et al
    The impact of COVID-19 on young people's mental health, wellbeing and routine from a European perspective: A co-produced qualitative systematic review.
    PLoS One. 2024;19:e0299547.
    PubMed         Abstract available
    
    
43. JIMA LM, Atomsa GE, Allard JP, Nigatu YD, et al
    The effect of malnutrition on adult Covid-19 patient's ICU admission and mortality in Covid-19 isolation and treatment centers in Ethiopia: A prospective cohort study.
    PLoS One. 2024;19:e0298215.
    PubMed         Abstract available
    
    
44. MONESS H, Mousa SO, Mousa SO, Adel NM, et al
    Thrombophilia genetic mutations and their relation to disease severity among patients with COVID-19.
    PLoS One. 2024;19:e0296668.
    PubMed         Abstract available
    
    
45. MOUSAVI R, Gu B
    When local governments' stay-at-home orders meet the white house's "opening up america again".
    PLoS One. 2024;19:e0298115.
    PubMed         Abstract available
    
    
46. LAGOS-ALVAREZ B, Zaldua Flores S, Figueroa-Zuniga J, Novoa-Munoz F, et al
    Surveillance of the recurrence time of the effectiveness of national and region-level quarantines of COVID-19 pandemic in Chile.
    PLoS One. 2024;19:e0295368.
    PubMed         Abstract available
    
    
47. MORISI D, Clolery H, Kon Kam King G, Schaub M, et al
    How COVID-19 affects voting for incumbents: Evidence from local elections in France.
    PLoS One. 2024;19:e0297432.
    PubMed         Abstract available
    
    
48. KOSKAN A, Larkey L, Todd M, Kim SW, et al
    Protocol for a community-based digital storytelling pilot intervention to reduce Hispanic parents' vaccine hesitancy to immunize their children against COVID-19.
    PLoS One. 2024;19:e0299787.
    PubMed         Abstract available
    
    
49. MAHMOUDIANI S
    Prevalence and dynamics of contraceptive use by type during the COVID-19 pandemic: Evidence from Western Iran.
    PLoS One. 2024;19:e0300613.
    PubMed         Abstract available
    
    
50. TRZEBINSKI W, Trzebinski J
    How does collectivism help deal with perceived vaccine artificiality? The case of COVID-19 vaccination intent in European young adults.
    PLoS One. 2024;19:e0300814.
    PubMed         Abstract available
    
    
51. LEUNG H, Lim M, Lim WO, Lee SA, et al
    Psychological well-being of healthcare workers during COVID-19 in a mental health institution.
    PLoS One. 2024;19:e0300329.
    PubMed         Abstract available
    
    
52. VAN HAGEN CCE, Huiberts AJ, Mutubuki EN, de Melker HE, et al
    Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies.
    PLoS One. 2024;19:e0300324.
    PubMed         Abstract available
    
    
53. TSOU HH, Lee FJ, Wu SI, Fan B, et al
    Suppression of the alpha, delta, and omicron variants of SARS-Cov-2 in Taiwan.
    PLoS One. 2024;19:e0300303.
    PubMed         Abstract available
    
    
54. CHUME FC, Freitas PAC, Schiavenin LG, Sgarioni E, et al
    Glycated albumin in the detection of diabetes during COVID-19 hospitalization.
    PLoS One. 2024;19:e0297952.
    PubMed         Abstract available
    
    
55. STOSIC M, Plavsa D, Jovanovic V, Veljkovic M, et al
    Factors associated with COVID-19 among hospitalized patients with severe acute respiratory infections in Serbia, 2022-2023: A test negative case-control study.
    PLoS One. 2024;19:e0299210.
    PubMed         Abstract available
    
    
56. SAEED F, Ghalehnovi E, Saeidi M, Ali Beigi N, et al
    Factors associated with suicidal ideation among medical residents in Tehran during the COVID-19 pandemic: A multicentric cross-sectional survey.
    PLoS One. 2024;19:e0300394.
    PubMed         Abstract available
    
    
57. MELCHIORRE MG, Cerea S, Socci M, Lamura G, et al
    The impact of the COVID-19 pandemic on frail older people ageing in place alone in two Italian cities: Functional limitations, care arrangements and available services.
    PLoS One. 2024;19:e0298074.
    PubMed         Abstract available
    
    
58. LUU MN, Imoto A, Matsuo Y, Huy NT, et al
    Anxiety and its risk factors among non-Japanese residents living in Japan undergoing COVID-19 situation: A cross-sectional survey.
    PLoS One. 2024;19:e0280144.
    PubMed         Abstract available
    
    
59. WOLLAST R, Schmitz M, Bigot A, Brisbois M, et al
    Predicting health behaviors during the COVID-19 pandemic: A longitudinal study.
    PLoS One. 2024;19:e0299868.
    PubMed         Abstract available
    
    
60. MISQUITTA K, Miller BM, Malecek K, Gleason E, et al
    A fluorescence viewer for rapid molecular assay readout in space and low-resource terrestrial environments.
    PLoS One. 2024;19:e0291158.
    PubMed         Abstract available
    
    
61. LUVIANO-GARCIA JA, Loose-Esparza A, Hernandez-Ruiz YG, Sanz-Sanchez MA, et al
    Risk factors for intubation and mortality in patients treated with high flow nasal cannula due to COVID-19 infection. Survival Analysis Study in a Northern Mexican Population.
    PLoS One. 2024;19:e0296931.
    PubMed         Abstract available
    
    
62. DE VRIES N, Maniscalco L, Matranga D, Bouman J, et al
    Determinants of intention to leave among nurses and physicians in a hospital setting during the COVID-19 pandemic: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0300377.
    PubMed         Abstract available
    
    
63. OTTO AK, Prinsloo S, Natori A, Wagner RW, et al
    Impact of COVID-19-related experiences on health-related quality of life in cancer survivors in the United States.
    PLoS One. 2024;19:e0297077.
    PubMed         Abstract available
    
    
64. ARUMAE K, Realo A, Ausmees L, Allik J, et al
    Self- and informant-reported personality traits and vaccination against COVID-19.
    PLoS One. 2024;19:e0287413.
    PubMed         Abstract available
    
    
65. KANTE DSI, Jebrane A, Boukamel A, Hakim A, et al
    Morocco's population contact matrices: A crowd dynamics-based approach using aggregated literature data.
    PLoS One. 2024;19:e0296740.
    PubMed         Abstract available
    
    
66. TARIQ MU, Ismail SB
    Deep learning in public health: Comparative predictive models for COVID-19 case forecasting.
    PLoS One. 2024;19:e0294289.
    PubMed         Abstract available
    
    
67. GIVI J, Fitzgerald MP
    The first-to-test bias: Impact of testing order on assigning responsibility for contagion.
    PLoS One. 2024;19:e0297965.
    PubMed         Abstract available
    
    
68. LEE KS, Go MJ, Choi YY, Kim MK, et al
    Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service.
    PLoS One. 2024;19:e0300306.
    PubMed         Abstract available
    
    
69. AZZERI A, Mohamed NA, Wan Rosli SH, Abdul Samat MN, et al
    Unravelling the link between SARS-CoV-2 mutation frequencies, patient comorbidities, and structural dynamics.
    PLoS One. 2024;19:e0291892.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

70. FLECKENSTEIN F, Stephan S, Hasse H
    Elucidating the behavior of the SARS-CoV-2 virus surface at vapor-liquid interfaces using molecular dynamics simulation.
    Proc Natl Acad Sci U S A. 2024;121:e2317194121.
    PubMed         Abstract available
    
    
71. GAO R, Xu X, Kumar P, Liu Y, et al
    Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for SARS-CoV-2 variants.
    Proc Natl Acad Sci U S A. 2024;121:e2310469121.
    PubMed         Abstract available
    
    

    
    Vaccine

72. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
73. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
74. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
75. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
76. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
77. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
78. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed         Abstract available
    
    
79. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
80. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
81. LANG JC, Kura K, Garba SM, Elbasha EH, et al
    Comparison of a static cohort model and dynamic transmission model for respiratory syncytial virus intervention programs for infants in England and Wales.
    Vaccine. 2024;42:1918-1927.
    PubMed         Abstract available
    
    
82. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
83. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
84. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
85. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
86. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
87. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    PubMed        
    
    
88. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
89. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
90. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
91. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
92. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    PubMed        
    
    
93. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
94. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
95. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
96. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
97. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
98. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    

    
    Virology

99. SAKA N, Nishio M, Ohta K
    Human parainfluenza virus type 2 V protein inhibits mitochondrial apoptosis pathway through two ways.
    Virology. 2024;594:110053.
    PubMed         Abstract available
    
    

    
    Virus Res

100. JANSEN JM, Meineke R, Molle A, van de Sandt CE, et al
     Selective pressure mediated by influenza virus M1(58-66) epitope-specific CD8(+)T cells promotes accumulation of extra-epitopic amino acid substitutions associated with viral resistance to these T cells.
     Virus Res. 2024;343:199355.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.